These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30232538)

  • 41. Treatment and Management of Osteoporotic Fractures: A Nation-wide Survey of 484 Senior Orthopaedists in China.
    Man Y; Pan W; Lu J; Li SY; Zhang P; Guo JZ; Yu SF; Zhang B; Xiao E; Zhang C; Zuo W; Jin HJ; Chen Y; Wu B; Shi XE; Hong D; Liu X; Gao YX; Li J; Yin L; Xue QY
    Orthop Surg; 2016 Nov; 8(4):432-439. PubMed ID: 28032704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is a reasonable rate for specific osteoporosis drug therapy in older fragility fracture patients?
    Gosch M; Bail HJ; Grueninger S; Stumpf U; Kammerlander C; Wicklein S
    Arch Osteoporos; 2020 Feb; 15(1):20. PubMed ID: 32088765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
    Kim SJ; Cho YJ; Lee DW
    Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
    Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
    Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study.
    Senay A; Fernandes JC; Delisle J; Morin SN; Perreault S
    Arch Osteoporos; 2019 Aug; 14(1):87. PubMed ID: 31375983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
    Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
    Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial.
    Solomon DH; Gleeson T; Iversen M; Avorn J; Brookhart MA; Lii J; Losina E; May F; Patrick A; Shrank WH; Katz JN
    Osteoporos Int; 2010 Jan; 21(1):137-44. PubMed ID: 19436935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using a sequential explanatory mixed method to evaluate the therapeutic window of opportunity for initiating osteoporosis treatment following fragility fractures.
    Roux S; Gaboury I; Gionet-Landry N; Garant MP; Beaulieu MC; Carrier N; Cabana F; Boire G
    Osteoporos Int; 2018 Apr; 29(4):961-971. PubMed ID: 29445831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial.
    Jaglal SB; Donescu OS; Bansod V; Laprade J; Thorpe K; Hawker G; Majumdar SR; Meadows L; Cadarette SM; Papaioannou A; Kloseck M; Beaton D; Bogoch E; Zwarenstein M
    Osteoporos Int; 2012 Jan; 23(1):87-95. PubMed ID: 21779817
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Barriers to secondary fracture prevention in primary care.
    Mendis AS; Ganda K; Seibel MJ
    Osteoporos Int; 2017 Oct; 28(10):2913-2919. PubMed ID: 28664275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of osteoporotic refractures in regional Australia.
    Davidson E; Seal A; Doyle Z; Fielding K; McGirr J
    Aust J Rural Health; 2017 Dec; 25(6):362-368. PubMed ID: 28618161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study.
    Tasci I; Cintosun U; Safer U; Naharci MI; Bozoglu E; Aydogdu A; Doruk H
    Acta Clin Belg; 2018 Aug; 73(4):237-243. PubMed ID: 29251181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.